Author of

• 25962

  +

  P3.08 - Oligometastatic NSCLC (Not CME Accredited Session) (ID 974)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27568

    +

    P3.08-13 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series (ID 11229)

    12:00 - 13:30  |  Author(s): Lana Schumacher
    • Abstract
    • Slides

    Background
    

    Lung metastases from a primary extrapulmonary malignancy often represent widespread metastatic disease. There are circumstances, however, where disease may truly be limited. For patients that cannot undergo surgical metastatectomy, SBRT represents a non-invasive option. Herein, we report the results of using lung SBRT to treat limited lung lesions from extrapulmonary malignancies.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We retrospectively reviewed outcomes in 44 patients with 50 lung nodules treated with SBRT. Fifty percent of the patients were male and median age was 64 (38-86). The median number of nodules was 1 (1-3) and almost all patients had oligometastatic disease (90%). Thirty-four percent of patients had extrathoracic disease. Primary malignancies included bladder (2%), breast (14%), endometrial (7%), Ewings sarcoma (2%), cholangiocarcinoma (2%), colon cancer (30%), rectal cancer (20%), small bowel (2%), head and neck (14%), renal cell (5%), and thyroid (2%). Seventy-five percent of patients had systemic therapy prior to any lung SBRT.

    4c3880bb027f159e801041b1021e88e8 Result
    

    As above, 50 lung nodules were treated with SBRT in 44 patients. Median dose was 48 Gy (36-54 Gy) in 5 fractions (3-8). This dosing scheme yielded a median BED₁₀ of 100 Gy (60-105.6 Gy). Follow up imaging was available for review in 96% of nodules. Median follow up from SBRT was 17.5 months (1-68). One year local control was 82%. BED₁₀>72Gy predicted improved local control (90% vs 57% at 1 year). Local control was inversely related to SUV on pre treatment PET/CT using a cut off of 4. If lesions had SUV>4.0 local control was 67% compared to 92% at one year. One year overall survival from SBRT was 66%. There was no difference in OS if patients had extrathoracic disease. Forty-six percent of patients had distant failure at 6 months. There was no acute or late grade 3 or higher toxicity.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Lung SBRT is an effective and safe tool for treatment of limited lung metastases. Dose selection remains important for local control, and lesions with increased SUV show higher predilection for local failure.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.